crucially to the pathological angiogenesis provoked by hypoxia of the retina in rodents, playing a major role in ocular neovascularization. 12 Therefore, we hypothesized that GCPII expression may be involved in intraplaque neovascularization. Radiolabelled GCPII ligands, such as 68 Ga-PSMA I&T, have recently been introduced and are increasingly applied in clinical image-based staging procedures. 10, 13 Intriguingly, vascular GCPII ligand accumulation is observed frequently in oncological positron emission tomographic (PET) studies.
PET/computed tomography (CT) is increasingly applied to further characterize pathophysiologic processes in atherosclerotic plaque. 18 F-Fluorodeoxyglucose (FDG) PET has become an established method for the quantification of macrophage-mediated inflammation in atherosclerotic lesions. [14] [15] [16] Other radiotracers target different pathophysiologic aspects of atherosclerotic plaque, including active microcalcification, 17, 18 fatty acid synthesis, 19 and macrophage infiltration. 20 Plaque neovascularization has previously been visualized using 18 F-galacto-RGD (arginine-glycine-aspartic acid) PET/CT, targeting αvβ3 integrin expression by angiogenic endothelial cells in atherosclerotic lesions. 21 To date, there are no data concerning the potential of 68 Ga-GCPII ligand PET/CT for the functional characterization of atherosclerotic plaque.
Therefore, the purpose of the present study was to assess the feasibility of 68 Ga-GCPII ligand PET/CT for noninvasive clinical molecular imaging of plaque neovascularization. To this end, we retrospectively analyzed various arterial segments in 68 Ga-GCPII ligand PET/CT scans obtained for the investigation of malignant tumors and compared imaging findings with calcified plaque (CP) burden, representing an established imaging-based surrogate for plaque and cardiovascular risk factors.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results
68 Ga-GCPII ligand uptake and CP burden could be measured in all patients. Relevant clinical characteristics of included patients are reported in Table 1 .
Reproducibility
The intrarater Cohen κ was 1.0 (95% confidence interval [CI], 1.0-1.0) for calcification in arterial segments and 0.98 (95% CI, 0.94-1.0) for 68 Ga-GCPII ligand uptake, indicating a perfect or very good strength of agreement, respectively. The interrater Cohen κ was 0.99 (95% CI, 0.97-1.0) for calcification in arterial segments and 0.94 (95% CI, 0.86-1.0) for 68 Ga-GCPII ligand uptake, indicating a very good strength of agreement.
Arterial Wall 68 Ga-GCPII Ligand Uptake and CP Burden

Radiotracer Uptake
Focally increased vascular uptake of the 68 Ga-GCPII ligand was detected at 5776 sites in 149 (99.3%) of the 150 study patients. The number of uptake sites was highest in the thoracic aorta, followed by the femoral arteries and the abdominal aorta. Mean maximum standardized uptake value was 2.5±0.8, and values ranged from 0.8 to 8.6. Mean bloodpool standardized uptake value was 1.4±0.3 (range, 0.6-2.1). Mean target-to-background ratio (TBR) was 1.8±0.6, and values ranged from 1.0 to 7.2. TBR was highest in the thoracic aorta. Detailed data on the prevalence and intensity of arterial tracer accumulation are provided in Table 2 .
CP Burden
CPs were observed at 5905 sites in 146 (97.3%) of the 150 study patients. On average, 6.4±4.3 (range, 1-40) CPs were found in each arterial segment with discernible calcification. The prevalence of CP was highest in the abdominal aorta, followed by the femoral arteries and the thoracic aorta. Mean calcified lesion thickness was 3.3±1.5 mm (range, 0.5-11.5 mm). Mean calcification score was 1.5±1.2 (range, 0-4). Detailed data on the prevalence, distribution, and extent of calcification in the studied vasculature are provided in Table I On a per-segment basis, 1056 (88.0%) of 1200 arterial segments were PET+, 846 (70.5%) were CT+, 789 (65.8%) were PET+/CT+, 267 (22.3%) were PET+/CT−, 57 (4.8%) were PET−/CT+, and 87 (7.3%) were PET−/CT−. Examples of arterial wall segments with 68 Ga-GCP II ligand uptake with and without concomitant calcification are shown in 
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Relationship Among 68 Ga-GCPII Ligand Uptake, CP Burden, and Risk Factors
When the topographical relationship between arterial 68 Ga-GCPII ligand accumulation and calcification sites was analyzed on a per-lesion basis, the majority (4713/5776; 81.6%) of PET+ lesions did not correspond to CT+ calcification. In only 1063 (18.4%) PET+ arterial lesions, concordant calcification was observed in at least some part of the affected vessel wall.
Consistent with these findings, no statistical correlation was found between the number of CPs (an established marker of atherosclerosis) and the number of PET+ arterial uptake sites on a patient-by-patient basis (r s =0.13; P=0.12). Likewise, the severity of arterial calcification, as determined by either calcification score (r s =0.03; P=0.72) or maximum plaque thickness in the vasculature (r s =0.09; P=0. 26) , was not associated with the number of PET+ arterial uptake sites. The number of exhibited risk factors showed a significant correlation with the number of CPs (r s =0.27; P=0.001) but not with the number of arterial tracer uptake sites (r s =0.003; P=0.98).
In univariate analysis, the number of CPs was significantly associated with age (2.12-fold more CPs; 95% CI, 1.63-2.77; P<0.0001), arterial hypertension (1.78-fold more CPs; 95% CI, 1.35-2.34; P<0.0001), history of smoking (1.61-fold more CPs; 95% CI, 1.21-2.13; P=0.001), and previous cardiovascular events (1.56-fold more CPs; 95% CI, 1.01-2.42; P=0.04). Patients on statin medication had more CPs (1.67-fold; 95% CI, 1.18-2.36; P=0.004). In multivariate analysis, age (1.99-fold more CPs; 95% CI, 1.55-2.54; P<0.0001), arterial hypertension (1.61-fold more CPs; 95% CI, 1.26-2.07; P=0.0002), and a history of smoking (1.52fold more CPs; 95% CI, 1.18-1.95; P=0.001) were significantly associated with the number of CPs as independent factors. Furthermore, multivariate analysis identified no significant association between number of CPs and body mass index, presence of diabetes mellitus, hypercholesterolemia, or previous cardiovascular events.
Conversely, no significant association was found between 68 Ga-GCPII ligand TBR and cardiovascular risk factors in either univariate or multivariate analysis. However, in multivariate regression analysis, there was a significant association between maximum TBR and injected dose, meaning that patients with higher injected doses had lower TBRs (difference of means, −0.2623; 95% CI, −0.4072 to −0.1174; P=0.0005). In addition, obese patients exhibited higher TBRs (difference of means, 0.21; 95% CI, 0.06-0.36; P=0.007) than nonobese patients ( Figure 3 ). When injected dose and overweight were modeled as independent factors, their effects persisted after both multivariate modeling and backward elimination. In addition, on multivariate analysis, obese patients had significantly more PET+ arterial uptake sites than nonobese patients (1.19-fold more lesions; 95% CI, 1.03-1.38; P=0.0154). When comparing symptomatic patients with a history of previous cardiovascular events and those without, TBR was not significantly different between both groups (1.7±0.3 versus 1.7±0.5; P=0.91). The number of PET+ lesions was also not significantly higher in patients with a history of previous cardiovascular events (40±19 versus 38±15; P=0.86).
When analyzing the relationship between organs that accumulate free gallium and maximum 68 Ga-GCPII ligand TBR in a subcohort of 50 randomly selected patients, TBR did not significantly correlate with hepatic uptake (r s =−0.02; P=0.91) or splenic uptake (r s =0.04; P=0.81).
Expression of GCPII in Carotid Specimens
To determine the relationship between GCPII expression and atherosclerotic plaque, tissue sections of human carotid specimens with and without luminal stenosis were stained for CD31 to visualize endothelial cells and for GCPII. Whereas CD31 staining identified multiple small vessels in the atherosclerotic vessel wall, particularly in the periphery of plaque, GCPII staining was not detected. By contrast, strong GCPII staining was observed in positive control tissue sections of human prostate epithelium (Figure 4 ).
Autoradiography of GCPII in Carotid Specimens
Quantitative autoradiographic analysis of carotid specimens did not demonstrate significantly different 68 Ga-PSMA I&T uptake between symptomatic and asymptomatic specimens (0.061±0.028 versus 0.123±0.053 Bq/cm 2 ; P=0.152). Furthermore, there was no significant difference between blocked (preincubated with 100 nM cold PSMA) and unblocked sections of symptomatic (0.084±0.013 versus 0.061±0.028 Bq/cm 2 ; P=0.158) or asymptomatic (0.123±0.053 versus 0.157±0.101 Bq/cm 2 ; P=0.695) specimens.
PET Phantom Measurements
Because GCPII ligand uptake correlated with injected dose, a phantom study was conducted to assess the impact of injected activity on image noise. The percentage coefficient of variation in spheres and background increased as the activity concentration decreased (P=0.08). The effect of activity concentration on image noise is shown in Figure I in the onlineonly Data Supplement.
Discussion
To our knowledge, this is the first study that evaluates the potential usefulness of 68 Ga-GCPII ligand PET for imaging of plaque neovascularization. In an oncological cohort of 150 patients, arterial uptake foci were frequently observed. However, unlike calcified plaque, PET findings were not associated with established determinants of cardiovascular risk. Furthermore, immunohistochemistry failed to detect GCPII in atherosclerotic vessel walls, indicating that GCPII may not be a priority target for atherosclerosis imaging.
Arterial uptake foci on 68 Ga-GCPII ligand PET were observed in both calcified and noncalcified vessel wall alterations, and the distribution of tracer accumulation was, in part, consistent with established atherosclerotic topography; that is, most foci were noted in the thoracic aorta. 17, 19, 22 When analyzing the intensity of 68 Ga-GCPII ligand uptake in arterial lesions, the measured TBRs were comparable with those for other established tracers used for plaque imaging. In a study on vascular 18 F-FDG uptake, mean TBR in the abdominal aorta was 1.57±0.35. 23 In another study using 18 F-sodium fluoride for visualization of microcalcification in plaque, mean TBR was 2.3±0.7. 16 In the present study, the mean intensity of tracer uptake as determined by TBR was 1.8±0.6, demonstrating a good vascular contrast for 68 Ga-GCPII ligand PET.
We assessed calcified plaque, representing an established marker of atherosclerosis, to validate our imaging approach. With regard to the colocalization of arterial uptake foci and calcification sites, the findings of this study add novel observations about 68 Ga-GCPII ligand uptake compared with other tracers used for characterization of atherosclerotic lesions. Using 18 F-FDG as a marker of macrophage activity, several studies reported colocalization with calcification in ≈2% to 14% of sites. 16, 22, 24 When 18 F-sodium fluoride is used as an indicator of active microcalcification, uptake has been shown to coincide with calcification in ≤88% of sites. 17 In the present study, only 18.4% of GCPII uptake sites were colocalized to calcification, suggesting that tracer accumulation particularly occurs in the noncalcified vessel wall, which may indicate some association with pathophysiologic processes found in early atherosclerotic disease. 4 Interestingly, in as much as 18% of lesions with increased tracer uptake, concordant calcification was found in at least some part of the plaque. This phenomenon may be explained by nonspecific tracer retention by arterial calcifications, as has been described for 18 F-FDG. 25 However, it is currently unknown whether, or to what extent, nonspecific mechanisms are involved in the vascular accumulation of tracers other than 18 F-FDG.
With regard to the association of arterial uptake foci and cardiovascular risk, 68 Ga-GCPII ligand uptake did not demonstrate a statistically significant correlation with many established determinants of risk, including age, hypertension, hypercholesterolemia, previous cardiovascular events, diabetes mellitus, and smoking. This indicates that, in contrast with 18 F-FDG, 23 68 Ga-GCPII ligand uptake does not identify lesions linked to risk-bearing, vulnerable atherosclerotic plaque. This view is further supported by the fact that neither the number of PET+ plaques nor TBR was significantly higher in patients with high-risk plaque, that is, patients with a history of cardiovascular events. We also assessed calcified plaque as an established marker of atherosclerosis to demonstrate that cardiovascular risk factors are associated with imaging-based markers of atherosclerosis in this cohort and to validate the assessment of GCPII ligand uptake. To this end, we observed highly significant associations between CP burden and risk factors, such as age (P<0.0001) and arterial hypertension (P<0.0001), in this cohort, supporting CP burden as better suited to identify lesions associated with the presence of risk factors.
It is well-known that image noise on PET rises with increasing body mass index. Consistent with this phenomenon, we observed a significant association between body mass index and both the number of arterial uptake foci and their intensity (TBR; P=0.0154 and P=0.007, respectively), such that the number and activity of foci increased as the patients' weight increased. In a study by Chang et al, 26 incremental body mass index at 20 to 24.9 or 30 to 45 was associated with increased image noise by 38% or 47%, respectively. Furthermore, image noise could be reduced by increasing the injected dose. 26 In our study, we observed a significant association between the intensity of arterial uptake foci (TBR; P=0.0005) and injected dose, resulting in higher activity of foci with lower injected dose. Given these findings, one may hypothesize that a component of arterial uptake foci may derive from image noise and is, therefore, nonspecific. This view is further supported by the results of body phantom measurements, which demonstrated that image noise, as determined by the percentage coefficients of variation, increased as the activity concentration decreased, leading to poor image quality and clustering of activity in reconstructed PET images. In addition, injected doses tend to be lower for 68 Ga-labeled tracers compared with 18 F-labeled tracers, which, in combination with the wider positron range, may contribute to lower image quality. 27 Both factors may have contributed to the apparent detection of arterial tracer uptake in this study.
Known mechanisms resulting in the formation of new vessels within the plaque include local ischemia and inflammation. 28 Although GCPII has been emphasized in the context of hypoxia-induced neovascularization, it is possible that inflammation-driven neovascularization is less dependent on GCPII expression.
It is unlikely that focal arterial tracer uptake is caused by free 68 Gallium. PSMA I&T was found to be stable in blood (100% intact tracer) at 0.5 hour postinjection in previous studies. 29 Furthermore, the time frame for uptake of gallium by inflammatory cells exceeds the duration of the study protocol (60 minutes). After intravenous injection of carrier-free 67 Ga-citrate, >99% of the radioactivity present in the circulation is in the plasma, almost exclusively bound to transferrin. 30 Gallium, mainly in the form of transferrin-Ga complex, is delivered to the inflammatory lesions through capillaries with increased permeability. At the site of inflammation, some gallium is taken up by leukocytes. 31 However, these processes require time, and clinical 67 Ga scans for infection imaging are usually performed at 48 to 72 hours postinjection, evidencing that accumulation of unbound 68 Ga should not accumulate in inflammatory cells in this study. This concept is supported by the fact that TBR did not significantly correlate with hepatic uptake (r s =−0.02; P=0.91) or splenic uptake (r s =0.04; P=0.81).
Autoradiographic analysis confirmed low tracer binding in both asymptomatic and symptomatic plaque, providing an explanation for the observed arterial uptake foci in PET images. However, the signal could not be significantly decreased by blocking with cold PSMA ligand, evidencing that the observed tracer binding is nonspecific. In addition, tracer binding could not differentiate between asymptomatic and symptomatic lesions (P=0.152). Indeed, nonspecific tracer binding has been previously described for other PET tracers for imaging of plaque. 25 This study had some limitations. First, GCPII ligand uptake foci and GCPII expression in the arterial wall could not be directly compared for obvious reasons. In addition, the apparent lack of GCPII expression in human carotid tissue does not exclude the possibility that the protein is expressed at levels below the detection limit of our immunohistochemical analysis. Second, additional autoradiographic studies of arterial specimens may shed light on the precise nature of nonspecific radiotracer binding; for example, whether tracer binding occurs in necrotic plaque was not performed in this study. Third, only 1 radiotracer targeting GCPII expression, that is, 68 Ga-PSMA I&T, was evaluated in this study. However, it is unlikely that the assessment of additional tracers, such as 68 Ga-PSMA HBED-CC, would have delivered other results because immunohistochemistry could not demonstrate any expression of the target in the arterial wall. Fourth, this is a retrospective study and, therefore, hypothesis generating. Finally, because of the retrospective analysis of clinical data, we used an imaging protocol optimized for oncological imaging. Longer tracer circulation times may be used to optimize vascular contrast. In addition, tracer is accumulated in cancer lesions to some extent, lowering the available dose for binding to GCPII in atherosclerotic plaques. However, the absence of expression of GCPII in atherosclerotic plaques is the main reason limiting the usefulness of GCPII ligand PET. At 60 minutes postinjection, <1.5% of the injected activity is found per liter of blood because of rapid clearance from blood. 10 Therefore, it is unlikely that there is relevant blood activity at 60 minutes postinjection. In addition, calculation of TBR accounts for the influence of blood activity.
Conclusions
68
Ga-GCPII ligand does not identify vascular lesions associated with atherosclerotic risk. According to our results and additional phantom measurements, foci of tracer accumulation are likely caused by nonspecific tracer binding and are in part noise-related. Taken together, GCPII may not be a priority target for imaging of atherosclerotic lesions.
